CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $67.11M, lower than 95% of all stocks globally
- PositionReturn on equity is -238.7%, lower than 95% of its Biotechnology peers (median -21.7%)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
The statements on file don't all cover the same year: income statement FY2025, balance sheet FY2024, cash-flow statement FY2024. Each figure below is labelled with the year it comes from.
Financials view
Market Capitalization
67.11MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
-98.21%vs all stocks
Market Capitalization
67.11MUSDvs all stocks (USD)
Enterprise Value
49.61MUSDvs all stocks (USD)
Forward P/E
-0.4708xvs Biotechnology peers
Price to Book (MRQ)
5.42xvs Biotechnology peers
Enterprise to EBITDA
-1.49xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-69.27%vs Biotechnology peers
Return on Equity (TTM)
-238.68%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 9, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-33.23MUSDvs all stocks (USD)
Net Income (TTM)
-19.65MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-26.06MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-19.47MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 9, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-39.03MUSDvs all stocks (USD)
Pre-tax Income
-26.98MUSDFY2025 · Dec 31, 2025Net Income
-26.98MUSDFY2025 · Dec 31, 2025EBIT
-23.70MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-32.43MUSDFY2025 · Dec 31, 2025Research & Development
18.78MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
23.63MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-3.38MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.14MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
3.28MUSDFY2025 · Dec 31, 2025EPS (Basic)
-165.50USDFY2025 · Dec 31, 2025EPS (Diluted)
-165.50USDFY2025 · Dec 31, 2025Basic Shares Outstanding
162.97KSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
162.97KSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-26.98MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-28.21MUSDFY2024 · Dec 31, 2024Free Cash Flow
-28.42MUSDFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
51.18MUSDFY2024 · Dec 31, 2024Interest Paid
4.61MUSDFY2024 · Dec 31, 2024Starting Profit (CF Statement)
-38.51MUSDFY2024 · Dec 31, 2024Depreciation & Amortization
259.00KUSDFY2024 · Dec 31, 2024Stock-based Compensation
8.39MUSDFY2024 · Dec 31, 2024Other Non-cash Items
2.26MUSDFY2024 · Dec 31, 2024Change in Accounts Payable (CF)
-291.00KUSDFY2024 · Dec 31, 2024Change in Other Assets/Liabilities
-319.00KUSDFY2024 · Dec 31, 2024Capital Expenditures
-208.00KUSDFY2024 · Dec 31, 2024Purchase of Investments
0.00USDFY2024 · Dec 31, 2024Sale of Investments
0.00USDFY2024 · Dec 31, 2024Net Investing Cash Flow
-208.00KUSDFY2024 · Dec 31, 2024Long-term Debt Payments
-5.04MUSDFY2024 · Dec 31, 2024Other Financing Charges
-119.00KUSDFY2024 · Dec 31, 2024Net Financing Cash Flow
29.80MUSDFY2024 · Dec 31, 2024Shares Outstanding
18.59MSharesUpdated Jul 9, 2026Float Shares
18.59MSharesUpdated Jul 9, 2026Shares Short
70.71KSharesUpdated Jul 9, 2026Short Ratio
0.8800daysvs all stocks
Short % of Shares Outstanding
0.38%vs all stocks
% Held by Insiders
1.30%vs all stocks
% Held by Institutions
0.65%vs all stocks
Total Cash (MRQ)
8.76MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.4710USDUpdated Jul 9, 2026Total Debt (MRQ)
0.00USDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
7.91xvs Biotechnology peers
Book Value per Share (MRQ)
0.5790USDUpdated Jul 9, 2026Total Assets
55.48MUSDvs all stocks (USD)
Total Current Assets
52.80MUSDFY2024 · Dec 31, 2024Total Liabilities
43.15MUSDFY2024 · Dec 31, 2024Total Non-current Assets
2.69MUSDFY2024 · Dec 31, 2024Total Non-current Liabilities
26.20MUSDFY2024 · Dec 31, 2024Total Current Liabilities
16.96MUSDFY2024 · Dec 31, 2024Cash & Cash Equivalents
51.18MUSDFY2024 · Dec 31, 2024Accounts Payable
628.00KUSDFY2024 · Dec 31, 2024Short-term Debt
10.72MUSDFY2024 · Dec 31, 2024Deferred Revenue
637.00KUSDFY2024 · Dec 31, 2024Long-term Debt
21.54MUSDFY2024 · Dec 31, 2024Other Non-current Liabilities
4.66MUSDFY2024 · Dec 31, 2024Common Stock (Book)
6.00KUSDFY2024 · Dec 31, 2024Retained Earnings
-667.92MUSDFY2024 · Dec 31, 2024Total Shareholders' Equity
12.33MUSDvs all stocks (USD)
52-Week Low
2.03USDUpdated Jul 9, 202652-Week Change
-98.21%vs all stocks
50-Day MA
5.01USDUpdated Jul 9, 2026200-Day MA
105.78USDUpdated Jul 9, 2026Avg 10-Day Volume
121.18KSharesUpdated Jul 9, 2026Avg 30-Day Volume
98.96KSharesUpdated Jul 9, 2026Diluted EPS (TTM)
-102.01USDUpdated Jul 9, 2026Other Income / Expense
14.19MUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -238.7%, lower than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: -2.39Industry median: -0.22Industry P5: -1.66Peers compared: 261
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.55
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $67.11M, lower than 95% of all stocks globallySignificant
Market cap (USD): 67,109,131Global P5: 269,387,740.27
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Context Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Poolbeg Pharma plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Curiosis Inc.
Tier 1ProductionApproval-Gated PipelineRule
Eco Animal Health Group PLC
Tier 1ProductionApproval-Gated PipelineRule
Creo Medical Group plc
Tier 1ProductionApproval-Gated PipelineRule
Bonus BioGroup Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Y-Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRule
SkinBioTherapeutics Plc
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Faron Pharmaceuticals Oy
Tier 1ProductionApproval-Gated PipelineRuleRisk
Engene Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Wave Life Sciences Ltd.
3 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shenzhen Uugreenpower Electric Co., Ltd.
3 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Fulcrum Therapeutics Inc.
3 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated